Loading...
In 2007, the availability of a new antiretroviral class — HIV integrase inhibitors — significantly increased the proportion of HIV-infected patients achieving viral suppression. Inevitably, some individuals acquired resistance to the first such drug, raltegravir, which meant loss of the entire class, because the resistance profile of the second integrase inhibitor, elvitegravir, is virtually identical to that of raltegravir. An investigational integrase inhibitor, dolutegravir, has in vitro activity against many raltegravir-resistant viruses. In a recent manufacturer-sponsored, phase IIb, multicenter, open-label study (VIKING), researchers assessed the activity of this agent in a population of patients with raltegravir treatment failure and…